ACAD Key Stats
- Are These Top Performers A Sell? Fool May 21
- Hey 19 May 21
- The Most Hated Breakout Ever May 21
- Clean-Up Time May 21
- Why Keryx is Lagging But Acadia is Zooming (Hint: It's About NCE) May 21
- ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Addition... May 20
- Slightly Negative but Still Frothy May 20
- Small-Caps Out Front May 20
- ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index Business Wire May 20
- Too Many Questions Make This Thursday Mover a Sell May 20
ACAD Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). ACADIA Pharmaceuticals is up 892.1% over the last year vs S&P 500 Total Return up 28.33%, Insmed up 329.0%, and Arena Pharmaceuticals up 33.00%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for ACAD
Pro Report PDF for ACAD
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ACAD Pro Report PDF
Pro Strategies Featuring ACAD
Did ACADIA Pharmaceuticals make it into our Pro Portfolio Strategies?